双重药物重用:萨拉卡提尼布的例子
Raquel Ramos1,2, Nuno Vale1,2,3
1PerMed Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal.
International journal of molecular sciences
|April 27, 2024
概括
萨拉卡提尼布最初用于癌症,在治疗阿尔茨海默病和其他疾病如纤维化等方面显示出潜力. 研究正在探索改善其有效性和减少副作用的方法,以获得更广泛的治疗应用.
科学领域:
- 药理学 药理学 是一个学科.
- 药物重用 药物重用
- 在瘤学瘤学.
背景情况:
- 萨拉卡提尼布 (AZD0530) 是一种用于癌症开发的双 Src/Abl 抑制剂.
- 早期的试验显示了耐受性,但在癌症治疗中有效性和副作用有限.
- 最近的研究重点是改善saracatinib的治疗特性,并探索新的应用.
研究的目的:
- 审查萨拉卡提尼布不断变化的治疗场景.
- 突出其用于非癌症疾病,特别是阿尔茨海默病的重新用途.
- 评估其治疗纤维化和其他疾病的潜力.
主要方法:
- 2006-2024年临床前和临床试验数据的审查.
- 对研究纳米粒子输送和药理学组合的研究进行分析.
- 对萨拉卡提尼布在阿尔茨海默病,纤维化和其他疾病中的有效性进行研究的审查.
主要成果:
- 在几项癌症试验中,萨拉卡提尼布显示出有限的治疗作用和显著的不良影响.
- 对于阿尔茨海默氏症的重复治疗,使用较低的有效剂量 (125 mg) 显示出有希望的临床结果.
- 研究表明潜在的镇痛,抗过敏和抗纤维功能.
结论:
- 萨拉卡提尼布在瘤学之外具有潜力,特别是在阿尔茨海默氏症治疗中.
- 对药物输送系统和组合的持续研究可能会减轻毒性并提高疗效.
- 尽管FDA未批准,但其多样化的应用表明了显著的治疗前景.
关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.癌症 癌症 癌症 癌症 癌症临床试验是指临床试验中的临床试验.药物重用是为了改变药物的用途.临床前试验 临床前试验萨拉卡提尼布 (saracatinib) 是一种药物.更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.2K
05:10Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
9.6K
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Structure-Activity Relationships and Drug Design
708
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
708
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
